Table 1.
Cases of anti-LRP2 nephropathy concurrently diagnosed with lymphoma
| Author | Age/sex | Histological findings | IgG subclass distribution of deposits | Type of lymphoma | Treatment | Outcome |
|---|---|---|---|---|---|---|
| Gamayo et al. [1] | 74/M | Immune complex-mediated TIN with moderate chronicity | IgG4>IgG1>IgG2>Ig3 | LPL | Bortezomib, dexamethasone, and rituximab | Dialysis-dependent in <1 month |
|
| ||||||
| Gamayo et al. [1] | 70/M | Immune complex-mediated TIN with moderate chronicity | IgG1»Ig2/IgG4 | CLL | Rituximab | 2 months of follow-up: mild improvement in sCr |
|
|
||||||
| IgG3 negative | ||||||
|
| ||||||
| Ng et al. (current report) | 79/M | Immune complex-mediated TIN with moderate chronicity | IgG1»IgG4 | EMZL | Rituximab | 7 months of follow-up: dialysis-dependent |
|
|
||||||
| IgG2 and IgG3 negative | ||||||
LPL, lymphoplasmacytic lymphoma; CLL, chronic lymphocytic leukemia; EMZL, extranodal marginal zone lymphoma; LRP2, LDL receptor related protein 2; TIN, tubulointerstitial nephritis.